A recent stock exchange announcement from China-based Biocytogen (HKG: 2315) has highlighted a strategic partnership with GV Safety Assessment Platform (GVSAP), a preclinical Contract Research Organization (CRO) and subsidiary of GV Research Platform (GVRP) in India. This new collaboration will provide Indian researchers with access to Biocytogen’s innovative BioMice models and its extensive expertise in the field of humanized animal-based research models.
The financial details of the agreement were not disclosed in the announcement.- Flcube.com
